Literature DB >> 17630921

Smac/DIABLO and colon cancer.

Y M Anguiano-Hernandez1, A Chartier, S Huerta.   

Abstract

Apoptosis is a genetically programmed process of controlled and orderly cell suicide, which is critical for multicellular organisms during development and tissue homeostasis. In cancer, the ratio of apoptosis to cell division is altered, resulting in a net gain of malignant tissue. Tumor cells may acquire resistance to apoptosis by the expression of anti-apoptotic proteins, or by the down-regulation or mutation of pro-apoptotic mediators. In the classic pathway of apoptosis, this process is primarily coordinated by activation of caspases. Decreased expression of caspases inversely correlates with the aggressiveness of cancer. Increased activity of caspases renders cancer cells susceptible to chemoradiotherapeutic modalities. Thus, caspase activity is pivotal in carcinogenesis. The functions of activated caspases are inhibited by the binding of inhibitors of apoptosis (IAPs). The function of IAPs is regulated by pro-apoptotic protein Second Mitochondria-Derived Activator of Caspases (Smac) or Direct IAP Binding Protein with low isoelectric point, pI (DIABLO). Induction of apoptosis leads to increased mitochondrial permeability to Smac/DIABLO, which adheres to IAPs inhibiting their caspase-binding activity. The role of Smac/DIABLO, therefore, may have significant diagnostic and therapeutic features in carcinogenesis. The role of Smac/DIABLO in colorectal carcinogenesis is ill defined. Data continues to accumulate to suggest that decreased levels of Smac/DIABLO may be important in chemoradiation-resistance to apoptosis in advanced colon cancer. The aim of this review is to provide the available evidence of the role of Smac/DIABLO in colon carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630921     DOI: 10.2174/187152007781058631

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  5 in total

Review 1.  Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.

Authors:  Bruno Christian Koehler; Dirk Jäger; Henning Schulze-Bergkamen
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

Review 2.  ILP-2: A New Bane and Therapeutic Target for Human Cancers.

Authors:  Zhiliang Zhang; Siqi Xiang; Ruxia Cui; Hang Peng; Roy Mridul; Mingjun Xiang
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

3.  NHA-oc/NHA2: a mitochondrial cation-proton antiporter selectively expressed in osteoclasts.

Authors:  R A Battaglino; L Pham; L R Morse; M Vokes; A Sharma; P R Odgren; M Yang; H Sasaki; P Stashenko
Journal:  Bone       Date:  2007-09-26       Impact factor: 4.398

4.  How many diseases are colorectal cancer?

Authors:  A Greystoke; S A Mullamitha
Journal:  Gastroenterol Res Pract       Date:  2012-09-09       Impact factor: 2.260

5.  Identifying Novel Candidate Genes Related to Apoptosis from a Protein-Protein Interaction Network.

Authors:  Baoman Wang; Fei Yuan; Xiangyin Kong; Lan-Dian Hu; Yu-Dong Cai
Journal:  Comput Math Methods Med       Date:  2015-10-04       Impact factor: 2.238

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.